Tin tức & Cập nhật

Patients with cirrhosis using calcium channel blockers (CCBs) are not at increased risk of variceal haemorrhage, as reported in a retrospective study.

Treatment with telitacicept reduces proteinuria among patients with immunoglobulin A nephropathy (IgAN) compared with placebo, according to a phase III study presented at ASN Kidney Week 2025.

For individuals with persisting COVID-19 symptoms, a 3-month resistance exercise program appears to yield greater improvements in physical function and psychological well-being compared with usual care alone, as shown in a study.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a decrease in deaths and major adverse cardiovascular events (MACE) in high-risk patients, reports as study.

Exposure to adverse childhood experiences (ACEs) appears to result in developmental, academic, and behavioural concerns among kindergarten children, suggests a Singapore study.

Patients with persistent symptoms of achalasia may benefit from repeat per-oral endoscopic myotomy (POEM) following a failed initial procedure, suggests a study.

In the post hoc analysis of the phase III PROTECT trial, the non-immunosuppressive dual endothelin angiotensin receptor antagonist sparsentan remains superior to irbesartan for the treatment of immunoglobulin A nephropathy (IgAN).

Discontinuing treatment with GLP-1RAs before or early into pregnancy in women with obesity may lead to more gestational weight gain and increased risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy, according to a retrospective study.

In patients with first-episode psychosis, the cumulative incidence of unnatural deaths (mostly suicide) rises sharply during the first 10 years, while deaths from natural causes begin to increase after the first decade, a 25-year population-based cohort study in Hong Kong has shown.

Regular monitoring and recognizing tell-tale signs upon first presentation are important in managing endocrine immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs), for optimized cancer treatment outcomes, stressed Dr David Lui from the University of Hong Kong, at the 8^th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2025).